로딩 중…
지수 로딩 중…
L&C BIO Co.,LTD
290650· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩58,600+11.83%
2026-10-07
Financials
Valuation Metrics
L&C BIO Co.,LTD's Market Cap is ₩1.6T. At end of 2025 it was ₩1.6T. Ranked #262 of 2,420 in KR market (top 11%), #66 of 1,639 on KOSDAQ (top 4%), #27 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 12%) by Market Cap.
Investment Metrics(as of 2026-10-07)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.58T KRW | KR#262/2,420 Sec#27/231 |
| Revenue | 116.22B KRW | KR#1,333/2,420 Sec#84/231 |
| Net Income | -148.73B KRW | KR—/2,420 Sec—/231 |
| Total Assets | 477.43B KRW | KR#790/2,420 Sec#46/231 |
| Net Assets | 335.19B KRW | KR#674/2,420 Sec#43/231 |
| Employees | 135 | KR#1,404/2,420 Sec#113/231 |
| Value | ||
| P/B | 4.71x | KR#2,195/2,420 Sec#185/231 |
| P/S | 13.60x | KR#2,290/2,420 Sec#166/231 |
| EV/EBITDA | 81.46x | KR#1,435/2,420 Sec#94/231 |
| FCF Yield | -0.21% | KR—/2,420 Sec—/231 |
| Profitability | ||
| ROE | -44.37% | KR#2,256/2,420 Sec#191/231 |
| ROA | -31.15% | KR#2,323/2,420 Sec#203/231 |
| Op. Margin | 16.93% | KR#235/2,420 Sec#22/231 |
| Revenue Growth | 52.98% | KR#189/2,420 Sec#24/231 |
| Earnings Growth | -217.96% | KR#1,245/2,420 Sec#86/231 |
| Financial Health | ||
| Debt Ratio | 42.43% | KR#842/2,420 Sec#98/231 |
| Total Debt | 58.60B KRW | KR#941/2,420 Sec#63/231 |
| FCF | -3.25B KRW | KR#1,405/2,420 Sec#111/231 |
| Cash | 36.42B KRW | KR#894/2,420 Sec#59/231 |
| Current Ratio | 1.33x | KR#1,349/2,420 Sec#142/231 |
| Net Debt/EBITDA | 1.13x | KR#750/2,420 Sec#50/231 |
| Dividend | ||
| Div. Yield | 0.08% | KR#1,366/2,420 Sec#84/231 |
| Div. Growth | 0.00% | KR—/2,420 Sec—/231 |
| Performance | ||
| 1Y Return | 21.38% | KR#589/2,420 Sec#36/231 |
| 1M Return | 25.08% | KR#951/2,420 Sec#79/231 |
| From 52W High | -51.60% | KR#1,715/2,420 Sec#137/231 |
| 1Y MDD | -60.33% | KR#1,489/2,420 Sec#119/231 |
| Trading | ||
| Volume | 391,013 shares | KR#392/2,420 Sec#28/231 |
| Trading Value | 22.50B KRW | KR#196/2,420 Sec#14/231 |
| Foreign Own. | 24.69% | KR#168/2,420 Sec#6/231 |
| Per Share | ||
| EPS | -5,515 KRW | KR—/2,420 Sec—/231 |
| BPS | 12,428 KRW | KR#829/2,420 Sec#56/231 |
Company Info
동사는 2011년 설립된 조직공학 치료재료 전문 바이오 기업으로, 2018년 코스닥시장에 상장하였음. 연결대상 종속회사로 GMRC 등 4개사를 보유하고 있으며, 당분기 중 엘앤씨에이아이와 엘앤씨퓨처랩의 지분을 매각하였음. 동사는 인체조직이식재, 의료기기, 코스메슈티컬 제조·판매와 제약사업, 자회사 GMRC를 통한 기능성 화장품·건강기능식품 CRO사업, AI 화장품 추천 플랫폼 사업을 영위하고 있음. 엘앤씨바이오는 2011년에 설립되었으며 경기도 성남시에 본사를 두고 있습니다.